PepGen (PEPG) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PepGen (PEPG) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, losing 32.0% versus a loss of 68.9%. Phathom Pharmaceuticals is the larger company by market cap ($378.8 million vs $356.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PEPG | PHAT |
|---|---|---|
| Share price | $3.78 | $4.66 |
| Market cap | $356.31M | $378.82M |
| 1-day change | -3.82% | -8.27% |
| YTD return | -41.94% | -71.91% |
| 1-year return | -32.01% | -68.93% |
| 5-year return | — | -76.46% |
| Forward P/E | — | 5.18 |
| EPS (TTM) | $-0.77 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $175.11M |
| Revenue growth (YoY) | — | +216.93% |
| Net income (latest FY) | $-89.66M | $-221.25M |
| Gross margin | — | 87.09% |
| Operating margin | — | -91.36% |
| Net margin | — | -126.35% |
| 52-week high | $7.80 | $18.31 |
| 52-week low | $1.31 | $4.62 |
| Distance from 52-week high | -51.54% | -74.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +263.76% | +321.67% |
| Average volume | 3.26M | 1.45M |
| Shares outstanding | 94.26M | 81.29M |
| Employees | 53 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PEPG has outperformed PHAT by 36.9 percentage points over the past year.
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
PEPG vs PHAT FAQ
Which is bigger, PepGen or Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) is larger, with a market capitalization of $378.82M compared with $356.31M for PepGen (PEPG).
Which stock has performed better over the past year, PEPG or PHAT?
PEPG returned -32.01% over the past 12 months, compared with -68.93% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are PepGen and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.